Skip to content

Emergent Biosolutions EBS Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin56.1%+21.4pp34.7%+1.9pp32.8%-5.2pp38%
Free cash flow margin21.9%
Efficiency
Asset turnover0.5×-0.1×0.6×+0.2×0.4×+0.1×0.4×-0.2×
Inventory turnover-1.1×2.1×+0.1×2.1×+0.1×
Liquidity
Current ratio+1.3×3.7×+2.6×+0.1×-2.4×
Quick ratio2.4×+0.6×1.8×+1.2×0.5×-0.2×0.7×-1.8×
Cash ratio1.6×+0.9×0.7×+0.5×0.2×-0.4×0.5×-1.0×
Leverage
Debt-to-equity1.1×-0.3×1.4×0.0×1.4×+0.3×+0.5×
Debt-to-assets0.4×0.0×0.5×0.0×0.5×0.0×0.5×+0.2×
Per Share
Book value per share$9.22+1.2%$9.11-28.2%$12.68-54.2%$27.70-7.0%
Valuation
Market capitalization$411.74M+22.0%$518M+316%$124.52M-78.9%$589.18M-74.8%
Enterprise value$834.84M-2.6%$1.09B+22.3%$890.32M-35.2%$1.37B-47.9%
Price / sales0.6×+0.3×0.5×+0.4×0.1×-0.4×0.5×-0.8×
Price / book0.8×+0.2×1.1×+0.9×0.2×-0.2×0.4×-1.0×
EV / sales1.2×+0.3×+0.2×0.8×-0.4×1.2×-0.3×
Free cash flow yield34.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Emergent Biosolutions's profit margins?
Emergent Biosolutions (EBS) runs a 54.2% gross margin and a 15.0% operating margin, with a 9.6% net margin.
Where do Emergent Biosolutions's ratios come from?
Every ratio is computed from Emergent Biosolutions's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.